Carcinoid Tumor Clinical Trials
Here are the 6 most popular medical studies for carcinoid tumor
68Ga-DOTATATE PET Scan for Neuroendocrine Cancer
This trial is testing a new way to scan for neuroendocrine cancer, which is often undetected by other methods. The new scan (68Ga-DOTATATE PET) will be compared to regular imaging methods to see if it is more effective.
Radioactive Drug
Lutetium Lu 177 Dotatate for Lung Carcinoid Tumor
This trial compares lutetium Lu 177 dotatate to the usual treatment, everolimus, for patients with neuroendocrine tumors that have spread to other parts of the body. Lutetium Lu 177 dotatate may be more effective than everolimus and cause less harm to normal cells.
Popular filter options for carcinoid tumor trials
Neuroendocrine Tumors Clinical Trials
View 15 Neuroendocrine Tumors medical studies.
Behavioural Intervention
Virtual Reality Therapy for Gastrointestinal Cancer Pain
This trial will assess the impact of immersive VR on pain and other patient-reported outcomes for people with digestive tract malignancies, as well as differences between skills-based VR therapy and distraction VR therapy.
Tyrosine Kinase Inhibitor
Cabozantinib for Pancreatic Neuroendocrine Tumors
This trial compares cabozantinib to placebo in treating neuroendocrine or carcinoid tumors. Cabozantinib is a chemotherapy drug that targets specific tyrosine kinase receptors, which when blocked, may slow tumor growth.
Radioisotope Therapy
Personalized PRRT for Neuroendocrine Tumors
This trial is testing a new way to give a cancer treatment called peptide receptor radionuclide therapy (PRRT). In this new way, the amount of PRRT given to each person will be different and personalized, based on how their body is expected to absorb the therapy. The goal is to maximize the amount of PRRT that gets to the tumor, while minimizing the amount that gets to healthy organs.
DSNET Clinical Trials
View 15 DSNET medical studies.
Behavioural Intervention
Virtual Reality Therapy for Gastrointestinal Cancer Pain
This trial will assess the impact of immersive VR on pain and other patient-reported outcomes for people with digestive tract malignancies, as well as differences between skills-based VR therapy and distraction VR therapy.
Tyrosine Kinase Inhibitor
Cabozantinib for Pancreatic Neuroendocrine Tumors
This trial compares cabozantinib to placebo in treating neuroendocrine or carcinoid tumors. Cabozantinib is a chemotherapy drug that targets specific tyrosine kinase receptors, which when blocked, may slow tumor growth.
Radioisotope Therapy
Personalized PRRT for Neuroendocrine Tumors
This trial is testing a new way to give a cancer treatment called peptide receptor radionuclide therapy (PRRT). In this new way, the amount of PRRT given to each person will be different and personalized, based on how their body is expected to absorb the therapy. The goal is to maximize the amount of PRRT that gets to the tumor, while minimizing the amount that gets to healthy organs.
Carcinoid Tumor Clinical Trials With No Placebo
View 21 carcinoid tumor medical studies that do not have a placebo group.
Radioisotope Therapy
Personalized PRRT for Neuroendocrine Tumors
This trial is testing a new way to give a cancer treatment called peptide receptor radionuclide therapy (PRRT). In this new way, the amount of PRRT given to each person will be different and personalized, based on how their body is expected to absorb the therapy. The goal is to maximize the amount of PRRT that gets to the tumor, while minimizing the amount that gets to healthy organs.
View More Carcinoid Tumor Trials
See another 5 medical studies focused on carcinoid tumor.
Frequently Asked Questions
Introduction to carcinoid tumor
What are the top hospitals conducting carcinoid tumor research?
In the realm of cutting-edge clinical trials for carcinoid tumors, several top hospitals are making significant strides. Tampa's Moffitt Cancer Center leads the way with four ongoing trials focused on this rare neuroendocrine tumor, supported by a track record of eight completed studies since their first recorded trial in 2007. Similarly, Cedars Sinai Medical Center in Los Angeles has also emerged as a formidable force in carcinoid tumor research, currently conducting four active trials and contributing to the field with four previous investigations dating back to 2007.
Moving further west to Houston's renowned M D Anderson Cancer Center, three ongoing clinical trials are dedicated to advancing our understanding and treatment options for carcinoid tumors. With eleven prior studies conducted since their initial trial in 2003, this institution continues to make valuable contributions towards overcoming challenges posed by this complex disease. Anchorage's Katmai Oncology Group may appear smaller-scale but demonstrates its commitment with three active carcinoid tumor trials and pioneering efforts that began only recently in 2013.
Lastly, located at Berkeley's Alta Bates Summit Medical Center-Herrick Campus we find another impactful player within this field; they have shown dedication through involvement in current trio of such tests while having contributed significantly despite limited numbers: their cumulative count stands equally at three from when they embarked upon recording its first-ever trial on these lines nearly thirteen years ago during 2007.
These esteemed hospitals represent beacons of hope for those affected by carcinoid tumors - an exceptionally rare form of cancer originating from hormone-producing cells known as neuroendocrine cells. By actively participating in clinical trials and pushing boundaries through scientific exploration and innovation, these institutions give patients reason to believe that breakthroughs may be just around the corner. Together, their collective efforts reinforce our determination to conquer not only the mysteries surrounding these unique tumors but also pave the way towards improved treatments and ultimately better outcomes for patients worldwide.
Which are the best cities for carcinoid tumor clinical trials?
When it comes to clinical trials for carcinoid tumors, several cities have emerged as top contenders. Los Angeles, California takes the lead with 21 active trials focusing on treatments like Bevacizumab, Nivolumab, and Pazopanib Hydrochloride. Following closely behind is Denver, Colorado with 17 ongoing studies investigating therapies such as Pazopanib Hydrochloride and Bevacizumab. Boston, Massachusetts also proves to be a hub for research in this field with 15 active trials exploring drugs like Cabozantinib and pembrolizumab. Anchorage, Alaska boasts 14 active trials studying Nivolumab, Pazopanib Hydrochloride, and Cabozantinib S-malate. Lastly, Honolulu,Hawaii has initiated 12 active trials primarily focused on Pazopanib Hydrochloride and Cabozantinib S-malate. These cities offer individuals battling carcinoid tumors access to cutting-edge clinical investigations that hold promise for improved treatment outcomes.
Which are the top treatments for carcinoid tumor being explored in clinical trials?
Carcinoid tumor research is making strides in clinical trials, with several promising treatments at the forefront. Leading the way is cabozantinib, currently being explored in two active trials dedicated to addressing carcinoid tumors. This drug has shown potential since its first listing in 2012 and has already garnered a total of two all-time clinical trials for this specific type of tumor. Another notable treatment under investigation is dual-energy computed tomography (DECT), which shows promise as a diagnostic tool for carcinoid tumors and has one active trial to support its efficacy. Additionally, PICO G2 4k and cabozantinib S-malate are also showing potential with one active trial each focused on combating carcinoid tumors. As researchers delve deeper into these innovative approaches, new avenues for treating carcinoid tumors may emerge, providing hope for patients worldwide.
What are the most recent clinical trials for carcinoid tumor?
Exciting advancements in the field of carcinoid tumor research offer hope for patients seeking new treatment options. Recent clinical trials have explored various approaches, including a combination of clinic and at-home treatments in Arm B, as well as dose escalation strategies. Additionally, randomized studies focusing on Paltusotine and RYZ101 have shown promising results in Phase 2 and Phase 3 trials respectively. Furthermore, EMB-01 has demonstrated potential benefits in both Phase 1 and Phase 2 testing. These groundbreaking efforts pave the way for improved outcomes and enhanced quality of life for individuals battling carcinoid tumors.
What carcinoid tumor clinical trials were recently completed?
In February 2011, H. Lee Moffitt Cancer Center and Research Institute concluded a significant clinical trial investigating the effectiveness of Pasireotide Long Acting Release (LAR) for carcinoid tumors. The completion of this trial marks an important milestone in understanding potential treatments for this type of tumor.